MONTREAL, QUEBEC--(Marketwire - November 29, 2007) - MethylGene Inc. (TSX: MYG) today announced that clinical results for its isotype-specific, histone deacetylase (HDAC) inhibitor, MGCD0103, currently in Phase II development with the Company’s partner Pharmion Corporation (NASDAQ: PHRM), will be presented in one oral and two poster presentations at the American Society of Hematology (ASH) 2007 Annual Meeting held in Atlanta from December 8 to 11, 2007.
